Study: NCT04969497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: M207 3.8 mg MiniMac
Description: Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: M207 3.8 mg MiniMac
Description: Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: M207 3.8 mg MiniMac
Description: Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: M207 3.8 mg MiniMac
Description: Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: M207 3.8 mg MACAP
Description: Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: M207 3.8 mg MACAP
Description: Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: M207 3.8 mg MACAP
Description: Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: M207 3.8 mg MACAP
Description: Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: M207 3.8 mg MACAP
Description: Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: M207 3.8 mg MACAP
Description: Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
Description: Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
Description: Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
Description: Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
Description: Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
Description: Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
Description: Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0